Toronto Innovation Acceleration Partners – TIAP – specializes in venture building of
early-stage health science technologies emerging from our members.
TIAP was formerly MaRS Innovation
Our Members
TIAP’s portfolio draws from the University of Toronto, seven teaching hospitals and two research institutes. Learn more about our members.Learn More›
Work With Us
Through our member-exclusive funding programs and services, TIAP works with founders to bring their health science technologies to market faster.Learn More›
Recent News

FedDev Ontario Funding Support – Portfolio Investments
On October 9, 2020, the Honourable Mélanie Joly, then Minister of Economic Development and Official Languages and Minister responsible for the Federal Economic Development Agency for Southern Ontario (FedDev Ontario) announced a FedDev …

TIAP and Evotec Expand LAB150 Bridge Partnership to Include Amgen
TIAP announced today the significant expansion of its flagship LAB150 drug discovery and development program with the addition of Amgen as a strategic and financial partner. Read full press release: https://bwnews.pr/3D3DUXb
LAB150 was created in 2017 …

Phase 2 clinical trial targeting diabetes
TIAP portfolio company Zucara Therapeutics moves their lead program targeting diabetes into Phase II clinical trials. Read more here.
Why this news is important:
Zucara has achieved the development milestones required to secure the remaining …

Highly Positive Results from PoC Phase 1b trial of ZT-01 – Type 1 Diabetes
Zucara Therapeutics announced highly positive results from its proof-of-concept Phase 1b trial of ZT-01 in people with Type 1 diabetes (“T1D”). Please see the press release here. Why this news is important:
This trial confirms ZT-01’s mechanism of action in restoring …